ReShape Lifesciences Inc. (RSLS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RSLS
- Company ReShape Lifesciences Inc.
- Price $4.91
- Changes Percentage 8.15
- Change 0.37
- Day Low $4.48
- Day High $4.95
- Year High $414.7
- Year Low $4.34
- Market Cap $3,351,778
- Price Avg 50 EMA (D) $9.87
- Price Avg 200 EMA (D) $100.49
- Exchange NASDAQ
- Volume 24,858
- Average Volume 701,875
- Open $4.48
- Previous Close $4.54
- EPS 264.12
- PE 0.02
- Earnings Announcement 2025-08-12 10:59:00
- Shares Outstanding $738,277
Company brief: RESHAPE LIFESCIENCES INC. (RSLS )
- Healthcare
- Medical - Devices
- Mr. Paul F. Hickey
- https://www.reshapelifesciences.com
- US
- N/A
- 10-06-2016
- US76090R2004
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.